SSGJ-612 is named as a drug or biological intervention in 3 clinical trials in our China trial register, 2 of which are recruiting. The lead sponsor is Shenyang Sunshine Pharmaceutical Co., LTD.. Registered phases: Phase 2 and Phase 1. Conditions studied include Metastatic Breast Cancer; Locally Advanced (Unresectable) or Metastatic Solid Tumors; Advanced Malignant Tumors.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07646626 | SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors (ClinicalTrials.gov ↗) Locally Advanced (Unresectable) or Metastatic Solid Tumors |
Phase 2 | Recruiting |
| NCT07032298 | A Phase I Study of SSGJ-612 in Patients With Advanced Solid Tumors (ClinicalTrials.gov ↗) Advanced Malignant Tumors |
Phase 1 | Recruiting |
| NCT07757230 | A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer (ClinicalTrials.gov ↗) Metastatic Breast Cancer |
Phase 2 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Metastatic Breast Cancer | 1 |
| Locally Advanced (Unresectable) or Metastatic Solid Tumors | 1 |
| Advanced Malignant Tumors | 1 |
| Lead sponsor | Trials |
|---|---|
| Shenyang Sunshine Pharmaceutical Co., LTD. | 3 |
| Register | SSGJ-612 trials |
|---|---|
| Clinical trials in China | 3 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how SSGJ-612 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists SSGJ-612 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.